Doctor consulting male patient, working on diagnostic examination on men's health disease or mental illness, while writing on prescription record information document in clinic or hospital office

Patient Resources

At Karyopharm, we keep the Patient at the forefront of everything that we do. Our core mission is to help patients by providing access to novel therapies and ongoing support, so they can live longer, higher-quality, and more functional lives.

We know a cancer diagnosis can be overwhelming and the treatment pathway can be complex.

Below are some additional resources that may be helpful for patients and their caregivers.

Clinical Trials

A clinical trial is a research study conducted to test whether a new treatment or drug is safe and how well it works in people. Certain requirements must be met to participate in a clinical trial, and there are some potential risks.

It is key to talk to your doctor about whether participating in a clinical trial is right for you.

For more information about ongoing clinical trials studying Karyopharm’s investigational medicines, please visit www.clinicaltrials.gov.

For a list of current Karyopharm and investigator sponsored clinical trials, click here.


Additional Patient Resources

There are many great organizations both in the U.S. and around the world that can provide educational and supportive resources to patients and their caregivers.

Below are some helpful resources:

Multiple Myeloma

The Multiple Myeloma Research Foundation

International Myeloma Foundation

HealthTree for Multiple Myeloma

Myeloma UK

Myeloma Canada

Lymphoma

The Lymphoma Research Foundation

The Leukemia & Lymphoma Society (LLC)

General Cancer Resources

American Cancer Society

CancerCare

National Comprehensive Cancer Network (NCCN)

NOTE: These links are provided as a convenience, and by including these links, we do not imply endorsement of the content of the external site. The content of these sites is managed by their owners and we have no control nor do we assume responsibility or liability for this third-party content.